Triptorelin: Uses, Mechanism, Evidence, and Side Effects

Men facing an advanced prostate cancer diagnosis often want to understand how hormone-based therapy actually works before starting it. Triptorelin is a long-studied synthetic hormone agonist with a defined label, a large trial footprint, and a well-characterized side effect profile.

Key takeaways

• Triptorelin is a synthetic GnRH agonist approved under the brand name Trelstar.
• It is indicated for the treatment of advanced prostate cancer.
• More than 300 registered trials have studied triptorelin or related GnRH agonist approaches.
• Reported adverse events in FDA safety data include death, fatigue, disease progression, and hot flush, reflecting a population with advanced disease rather than proven drug causation.
• The label does not carry a boxed warning.

What Triptorelin Is

Triptorelin is a synthetic decapeptide that mimics gonadotropin releasing hormone (GnRH), a natural signaling hormone. Laboratory studies show it is far more potent than native GnRH at stimulating luteinizing hormone release from pituitary cells and at binding pituitary GnRH receptors. By acting on this hormonal pathway, triptorelin alters downstream hormone signaling involved in disease processes such as prostate cancer growth.

What Triptorelin Is Approved For

Triptorelin, marketed as Trelstar, is approved for the treatment of advanced prostate cancer. As a GnRH agonist, it is used to suppress the hormonal signals that can drive progression of this cancer type. The label for Trelstar does not carry a boxed warning.

What the Evidence Shows

More than 300 trials have been registered that study triptorelin or closely related GnRH agonist strategies. Trial activity spans oncology and reproductive medicine, including a Phase 2 study of tracer-guided surgery for recurrent prostate cancer. Other registered trials have examined repeated GnRH agonist injection strategies and follicular response testing in non-oncology contexts, illustrating the breadth of research built around this hormonal mechanism.

Reported Side Effects

Safety surveillance reports for triptorelin include a wide range of events, with death, off-label use, and needle-related issues among the most frequently logged terms. Fatigue, disease progression, dose omission issues, hot flush, and reports of the drug being ineffective also appear with notable frequency. These figures represent raw report counts submitted to a passive surveillance system, not confirmed incidence rates or evidence that the drug caused the event, and many reports occur in patients with advanced, life-limiting cancer.